KNC Laboratories Co.,Ltd. (JP:6568)
:6568
Top Page
KNC Laboratories Co.,Ltd.
(6568)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥1,373.00
▲(22.15% Upside)
Action:DowngradedDate:10/31/25
The stock's overall score is driven primarily by its strong financial performance and reasonable valuation. Technical analysis indicates potential short-term weakness, but longer-term trends remain positive. The lack of earnings call and corporate events data limits further insights.
Positive Factors
Strong balance sheet
A consistently high equity ratio and low leverage provide durable financial flexibility. This supports capital allocation for R&D or capex, reduces refinancing risk in downturns, and underpins creditworthiness and long-term resilience of operations and investment plans.
Negative Factors
Recent revenue and EPS decline
A notable year-over-year decline in revenue and a sharp EPS contraction indicate rising pressure on top-line and earnings power. If these trends persist, they can erode reinvestment capacity, weaken margins, and signal competitive or demand setbacks with longer-term implications.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
A consistently high equity ratio and low leverage provide durable financial flexibility. This supports capital allocation for R&D or capex, reduces refinancing risk in downturns, and underpins creditworthiness and long-term resilience of operations and investment plans.
Read all positive factors
KNC Laboratories Co.,Ltd. (6568) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.87B
Dividend Yield2.98%
Average Volume (3M)2.89K
Price to Earnings (P/E)20.8
Beta (1Y)0.54
Revenue Growth-9.60%
EPS Growth-38.34%
CountryJP
Employees219
SectorBasic Materials
Sector Strength58
IndustryChemicals
Share Statistics
EPS (TTM)13.53
Shares Outstanding7,779,900
10 Day Avg. Volume3,150
30 Day Avg. Volume2,890
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)0.62
Price to Sales (P/S)1.02
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.6
Revenue Forecast (FY)¥12.00B
KNC Laboratories Co.,Ltd. Business Overview & Revenue Model
Company Description
KNC Laboratories Co., Ltd. engages in the research, development, and production solutions of organic chemicals in Japan. The company offers products for use in the pharmaceutical, electronic-chemical, agrochemical, energy, and environment fields. ...
How the Company Makes Money
null...
KNC Laboratories Co.,Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
65
Positive
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.18B | 9.15B | 8.63B | 7.44B | 6.03B |
| Gross Profit | 2.27B | 3.24B | 3.26B | 2.06B | 1.71B |
| EBITDA | 1.65B | 3.00B | 3.08B | 2.02B | 1.58B |
| Net Income | 737.33M | 1.49B | 1.54B | 643.46M | 399.68M |
Balance Sheet | |||||
| Total Assets | 20.20B | 18.71B | 15.47B | 14.03B | 12.88B |
| Cash, Cash Equivalents and Short-Term Investments | 2.39B | 3.31B | 2.30B | 1.97B | 1.96B |
| Total Debt | 3.12B | 1.97B | 1.54B | 1.68B | 1.44B |
| Total Liabilities | 6.68B | 5.62B | 3.73B | 3.46B | 2.76B |
| Stockholders Equity | 13.52B | 13.09B | 11.75B | 10.58B | 10.12B |
Cash Flow | |||||
| Free Cash Flow | -1.82B | 850.16M | 863.73M | -248.27M | 434.68M |
| Operating Cash Flow | 1.49B | 3.20B | 1.99B | 585.11M | 1.33B |
| Investing Cash Flow | -3.32B | -2.37B | -1.15B | -613.51M | -660.05M |
| Financing Cash Flow | 909.60M | 178.87M | -523.39M | 39.02M | -180.14M |
KNC Laboratories Co.,Ltd. Technical Analysis
Positive
1124.00
Price Trends
1234.80
Positive
1180.81
Positive
1135.20
Positive
Market Momentum
7.59
Negative
56.56
Neutral
81.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6568, the sentiment is Positive. The current price of 1124 is below the 20-day moving average (MA) of 1219.53, below the 50-day MA of 1234.80, and below the 200-day MA of 1135.20, indicating a bullish trend. The MACD of 7.59 indicates Negative momentum. The RSI at 56.56 is Neutral, neither overbought nor oversold. The STOCH value of 81.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6568.
KNC Laboratories Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥14.28B | 9.40 | ― | 1.81% | 9.07% | ― | |
69 Neutral | ¥9.87B | 20.79 | ― | 2.98% | -9.60% | -38.34% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ¥11.13B | 15.26 | ― | 1.06% | -9.63% | -1.71% | |
56 Neutral | ¥8.32B | 10.07 | ― | 1.93% | 13.64% | -151.98% | |
50 Neutral | ¥8.38B | 23.47 | ― | 2.97% | 9.92% | -27.64% |
* Basic Materials Sector Average
JP:6568
KNC Laboratories Co.,Ltd.
1,269.00
313.41
32.80%
JP:4360
MANAC Chemical Partners Co.,Ltd
965.00
461.08
91.50%
JP:4366
Daito Chemix Corporation
431.00
252.71
141.74%
JP:4531
Yuki Gosei Kogyo Co., Ltd.
384.00
152.85
66.13%
JP:4960
Chemipro Kasei Kaisya,Ltd.
677.00
402.07
146.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.